Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma

Table 1 Patients’ characteristics

Characteristic	n (%)
Age (yr)
Median	58 (37-74)
Gender
Male	63 (82.9)
Female	13 (17.1)
Stage1
II	21 (27.6)
III	27 (35.5)
IV	28 (30.3)
Fraction regimen
LCAF	16 (21.1)
CF	60 (78.9)
Number of chemotherapy cycles
1	8 (10.5)
2	13 (17.1)
3	7 (9.2)
4	48 (63.2)
Status
Survival	17 (22.4)
Dead	53 (69.7)
Lost to follow-up	6 (7.9)

¹UICC 6^th. LCAF: Late-course accelerated radiotherapy; CF: Conventional radiotherapy; UICC: Union for International Cancer Control.

Table 2 Prognostic factors for overall survival

Factor	No.	Median survival t/mo	Log-rank
Cycle(s)			0.013
1-3	26	16.1
4	50	35.5
Stage			0.037
II-III	48	36.1
IV	28	14.9
Gender			0.093
Male	63	17.3
Female	13	35.5
Age			0.708
< 65 yr	58	23.4
≥ 65 yr	18	27.0
Radiation			0.626
CF	60	23.4
LCAF	16	28.5

CF: Conventional radiotherapy; LCAF: Late-course accelerated radiotherapy.

Table 3 Results of TP regimen plus radiotherapy for loco-regionally advanced esophageal cancer in past studies

Ref.	No.	Chemotherapy	Dose and fraction	Grade ≥ 3 acute hematologic toxicity	Median observation period (mo)	Median survival t/mo	2-yr survival rate
Jingu et al[22]	84	PTX 135 mg/m2	50.4 Gy/28 fractions	40.00%	NA	14.9	37.00%
		DDP 75 mg/m2
		3-wk based
Tu et al[21]	36	PTX 135 mg/m2	52-70 Gy/1.8-2 fractions	13.90%	14	18	42.80%
		DDP 75 mg/m2
		3-wk based
Song et al[20]	82	PTX 135 mg/m2	60 Gy/30 fractions	30.50%	20.4	18.2	40.80%
		DDP 30 mg/m2
		4-wk based

DDP: Cisplatin; PTX: Paclitaxel; RT: Radiotherapy; NA: Not available.